NEORAL (TM) IN STABLE RENAL TRANSPLANT PATIENTS

环孢菌素A（CSA）口服给药的可预测性更高， 尽量减少亚治疗或毒性事件的数量和持续时间， 器官移植，从而提高同种异体移植物存活率。 我们有 最近确定，标准品的生物利用度 CSA制剂（Sandimmune）在稳定肾移植受者中的应用 在稳态条件下， 肝P4503A4活性。 最近，一种新开发的微乳液 CSA（Neoral）的配方已证明得到了改进， 与Sandimmune相比，可预测的生物利用度。 结果导致 CSA谷水平和AUC之间的相关性改善可能有助于 移植患者的管理，特别是CSA患者 吸收困难。 与以下因素相关的药代动力学改善 Neoral可能在很大程度上是由于微乳化CSA的能力， 绕过肠道代谢。

Greater predictability in the oral dosing of cyclosporin A (CSA) may minimize the number and duration of subtherapeutic or toxic events in organ transplantation, thus improving allograft survival. We have recently established that the bioavailability of the standard formulation of CSA (Sandimmune) in stable renal transplant recipients under steady state conditions is largely determined by both enteric and hepatic P4503A4 activity. Recently, a newly developed microemulsion formulation of CSA (Neoral) has demonstrated improved and more predictable bioavailability compared to Sandimmune. As a result, the improved correlation between trough CSA levels and AUC may facilitate the management of transplant patients, particularly those with CSA absorption difficulties. The improved pharmacokinetics associated with Neoral may be largely due to the ability of the microemulsified CSA to bypass enteric metabolism.